Clinical trials
Adverse Drug Event clinical trials
Below are recruiting adverse drug event clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06613165Recruiting
Short vs long treatment for stage II-III rectal cancer with dMMR
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
Xi'an, ShaanxiAges 18–80 - NCT06667687RecruitingPhase 1
Study of ABBV-291 for non-Hodgkin's lymphoma
This study tests an experimental drug called ABBV-291 for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two previous treatments. The goal is to see how safe it is, how well it works, and how the body processes it.
Huntersville, North CarolinaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06683092Recruiting
Restarting triple therapy with close monitoring for side effects
This trial tests whether carefully restarting a triple-combination CFTR modulator (VTD) is safe and helpful for people with cystic fibrosis who had to stop or change Trikafta because of mental health side effects or liver injury. You will be closely monitored with surveys and daily diaries to ensure your safety.
Birmingham, AlabamaAges 6 years+ - NCT06696755RecruitingPhase 2
Study of icalcaprant for bipolar depression
This study tests an oral medication called icalcaprant for adults with bipolar I or II who are currently in a depressive episode. The goal is to see if it reduces symptoms and whether it's safe when taken alongside your usual mood stabilizer.
Huntsville, AlabamaAges 18–65 - NCT06820970Recruiting
Combined therapy for heart artery blockages that weren't fully opened
This trial tests if combining a new heart procedure with a special type of therapy called mindfulness therapy can help prevent heart problems in people with coronary artery disease that could not be fully fixed with stents or surgery.
Zhengzhou, HenanAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07058454Recruiting
Heart safety study for targeted cancer therapies
This study looks at how targeted cancer treatments affect the heart. If you are an adult with any type of cancer and are getting or will get chemotherapy (including targeted drugs), joining this study helps doctors understand heart risks better.
Guangzhou, GuangdongAges 18 years+ - NCT07241039RecruitingPhase 1
Study of an oral drug for advanced squamous cell cancers
This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.
Duarte, CaliforniaAges 18 years+ - NCT07276997RecruitingPhase 2
Study of Icalcaprant for major depressive disorder
This trial tests an oral medication called icalcaprant for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms and what side effects may occur.
Dothan, AlabamaAges 18–65 - NCT01258231Recruiting
Genetic test to predict risks after heart surgery
This study looks for genetic (DNA) clues that may help predict side effects or complications after heart surgery. If you join, your genome information may be used to understand who is at higher risk and why.
Boston, MassachusettsAges 20–90 - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Duarte, CaliforniaAges 18 years+ - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+ - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT06192082Recruiting
Heart risks during painless stomach scope in frail elderly
This study looks at whether older, frail patients have heart problems during a painless stomach scope (gastroscopy). It aims to find safer ways to give sedation for these patients.
Beijing, Beijing MunicipalityAges 65–100 - NCT07448038RecruitingPhase 2
Study of selnoflast for heart artery inflammation
This trial tests a drug called selnoflast to see if it can reduce inflammation in the arteries of people with atherosclerosis (hardening of the arteries) who are at risk for heart attacks or other serious heart problems.
Beverly Hills, CaliforniaAges 18–80 - NCT07164833RecruitingPhase 2
Testing a drug to prevent kidney injury after heart surgery
This study tests a new medicine, BX-001N, to see if it can prevent kidney damage during and after heart surgery for aortic disease. It is for people with moderate kidney problems who are having planned surgery that stops the heart briefly.
DaeguAges 19–90 - NCT06909565RecruitingPhase 4
Inclisiran to prevent heart and leg events after artery procedure
This study tests whether a twice-yearly injection called inclisiran can prevent heart attacks, strokes, or leg complications in people who recently had a procedure to open a blocked artery. You may be eligible if you had a heart or leg artery procedure within the last two weeks.
Alexander City, AlabamaAges 18 years+ - NCT07354971Recruiting
Immuno-fit study for patients on immunotherapy
This study looks at how well patients with solid tumors who are receiving immunotherapy (checkpoint inhibitors) can exercise. It aims to see if exercise testing can help track your health during treatment.
Southampton, HampshireAges 18 years+
Hear when a new Adverse Drug Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse drug event?
- Yes. Clin2 currently lists 69 recruiting adverse drug event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse drug event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse drug event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.